MedTrace Logo

Safety and Efficacy of Travoprost/Timolol BAC-free

NCT00760539 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2014-07-16

No results posted yet for this study

Summary

The purpose of this study is to demonstrate equivalent safety and IOP-lowering effectiveness of two Travoprost/Timolol combination products in patients diagnosed with open-angle glaucoma or ocular hypertension. This global study will be conducted in the US (C-07-64, NCT00672997) and Japan (C-08-08, NCT00760539).

Conditions

Interventions

DRUG

Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution

DRUG

Travoprost 0.004%/Timolol 0.5% ophthalmic solution

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Pamela Smith, B.S. · Alcon Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00760539 on ClinicalTrials.gov